BioAmber Inc Stock Prediction and Forecast [BIOA]

AI-generated source summary

The analysis rates BioAmber Inc (BIOA) as a Strong Buy Candidate with a score of 8.221, reflecting a 187.50% gain over 54 days. The stock is identified within a broad, robust upward trend in the short term, with an anticipated retreat towards the lower trend section presenting a short-term selling opportunity. A breakout above $15.62 would signal accelerated growth. Over the next three months, a 155.57% increase is projected, leading to a target price of $39.38. The 12-month analysis suggests a 69.21% increase, with an anticipated price range of $13.15 to $26.08. On January 6th, 2026, BIOA closed at $15.41, a 22.11% gain, with increased volume and is 4.76% below its 52-week high of $16.18. Technical signals are mixed, with a short-term MACD sell signal, but buy signals from Pivots, Bollinger Bands, and Moving Averages. However, long-term Moving Averages show sell signals. The stock exhibits medium daily volatility (11.50%) and medium risk. Support is found at $13.39 and $12.62. The P/E ratio is negative (-7.29), indicating negative earnings with a consensus estimate of -$1.01 for Q4 2025. Insider trading shows significantly more buys than sells, reflecting positive sentiment. A suggested stop-loss is $14.86. For January 7th, 2026, BioAmber is expected to open lower at $14.63.

AI-generated summary based on the source content.

Evidence and evaluation progress

1. Original source published

   07 Jan 2026, 04:36 UTC

   The analyst published the original source item.

2. Source recorded by Tahlil Plus

   18 May 2026, 20:23 UTC

   The public source was preserved as the evidence record for this case.

3. Market predictions extracted

   18 May 2026, 20:48 UTC

   1 eligible signal linked to this case.

4. Outcome tracking started

   19 May 2026, 02:08 UTC

   Tahlil Plus began monitoring the extracted predictions.

5. First prediction resolved

   01 Aug 2026, 01:31 UTC

   The first evaluable outcome in this case reached a terminal result.

6. Case evaluation completed

   01 Aug 2026, 01:31 UTC

   All evaluable predictions in this case reached terminal outcomes.